SURAMIN IN PATIENTS WITH AIDS AND AIDS RELATED ILLNESSES

获得性免疫缺陷综合征(AIDS)是一种新发现的疾病 这会破坏人体抵抗感染的能力，并增加其 对某些形式的癌症的发展易感性。在一些 患者，卡波西肉瘤或侵袭性淋巴瘤的发展 艾滋病的第一个迹象是一种潜在的疾病。在另一些人中，机会主义 感染是本综合征的首发表现，也是最常见的 艾滋病患者的常见死因。认识到HTLV-III是 艾滋病的病原体和这种病毒在大范围内的可获得性 规模研究使测试可能的抗病毒药物成为可能。 体外活性。1984年10月，国家癌症研究所的调查人员 研究所报道，苏拉明通过以下途径在体外抑制HTLV-III 抑制病毒的细胞质酶，逆转录酶。 美国的几家机构一直在治疗患有 与苏拉明有关的艾滋病或艾滋病相关疾病。 在这份合同中，我们计划获得有关治疗的信息 艾滋病患者和艾滋病相关疾病患者使用苏拉明。

The acquired immunodeficiency syndrome (AIDS) is a newly recognized disease that destroys the body's capacity to fight infections and increases its susceptibility to the development of certain forms of cancer. In some patients, the development of Kaposi's sarcoma or an aggressive lymphoma is the first sign of AIDS as an underlying disorder. In others, opportunistic infection is the first manifestation of the syndrome and is the most frequent cause of death in AIDS patients. The recognition that HTLV-III is the etiologic agent of AIDS and the availability of this virus for large scale studies has made it possible to test drugs for possible antiviral activity in vitro. In October 1984, investigators at the National Cancer Institute reported that Suramin was able to inhibit HTLV-III in vitro by inhibiting the cytoplasmic enzyme of the virus, reverse transcriptase. Several institutions in the United States have been treating patients with AIDS or AIDS related illnesses with Suramin. In this contract we plan to acquire information about the treatment of patients with AIDS and AIDS-related illnesses with Suramin.